<DOC>
	<DOC>NCT01000740</DOC>
	<brief_summary>The primary objective is to describe the quality of life of long-term survivors who are not terminated from the EAP.</brief_summary>
	<brief_title>A Study on the Long Term Survivals in an Expand Access Program (EAP) of Iressa</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<criteria>Provision of informed consent prior to any study specific procedures. Participated in the Iressa EAP in China. Diagnosed as NSCLC. Patients who started EAP at least 3 years before this study initiated and have not yet terminated from the EAP (active longterm survivors). Patients who consent to provide blood sample and available archival tumour tissue sample for EGFR gene testing (provision of tumour tissue sample is optional). Patients who disagree to participate this study. Patients in whose medical objection was recorded to use the existing data from medical practice for scientific research.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2010</verification_date>
	<keyword>EAP</keyword>
	<keyword>Long term survival (3 years)</keyword>
	<keyword>Gefitinib</keyword>
	<keyword>efficacy</keyword>
</DOC>